VISTIN PHARMA ASA: årsregnskap 2022 vs 2021
Grew 9% on revenue, weaker earnings, cash halved-plus
approved 2023-04-26; registry 2023-07-03; journal 2023 533530
Summary
What changed
Comparing Årsregnskap 2022 with 2021 for VISTIN PHARMA ASA. Revenue 278.6k NOK → 304.9k NOK (+9.4%). Net result -2 558 NOK → -1.85m NOK. Equity 269.98m NOK → 268.13m NOK.
On the constructive side: revenue rose; operating result improved. Pressures included: net result weakened; equity eroded; cash fell.
Also worth watching: sharp cash drawdown; paid-in equity reduced; payroll increased. All figures are taken from the published annual accounts for VISTIN PHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 278.6k NOK to 304.9k NOK (+9.4% YoY). Calculated
-
↑
Operating result improved
Operating result -4.70m NOK → -4.19m NOK (op. margin -1686.1% → -1375.7%). Calculated
What deteriorated
-
↓
Net result weakened
Net result -2 558 NOK → -1.85m NOK (net margin -0.9% → -607.5%). Calculated
-
↓
Equity eroded
Book equity 269.98m NOK → 268.13m NOK (equity ratio 97.2% → 99.6%). Calculated
-
↓
Cash fell
Bank deposits 22.52m NOK → 1.39m NOK (-93.8% YoY). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (22.52m NOK → 1.39m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
Paid-in equity reduced
Paid-in equity fell 269.98m NOK → 268.13m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Payroll increased
Salary cost 1.95m NOK → 1.96m NOK (699% → 644% of revenue). Calculated
-
·
COGS moved
COGS / varekostnad 96.10m NOK → 138.06m NOK (+43.7% YoY). Calculated